Abstract
Low HDL-C has been associated with increased risk of CV events in both observational and prospective studies. The current ACC/AHA guidelines for cholesterol management recommend a possible role for non-statin therapy in patients with intolerance or under-expected response to statins. Niacin, a
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
